language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
WSTWST

$273.85

-3.34
arrow_drop_down1.20%
Current Market·update12 Nov 2025 21:00

$272.86

-0.99
arrow_drop_down0.36%
Pre-market·update13 Nov 2025 09:41
Day's Range
271.18-279.75
52-week Range
187.43-348.9

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2025-10-23
Next Earnings TimeBefore Market Open
Volume490.56K
Average Volume 30d661.43K

AI WST Summary

Powered by LiveAI
💰
41.84
Valuation (P/E Ratio)
Higher end, typical for growth companies
📈
0.0667
EPS Growth (YoY)
Positive earnings per share growth
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Buy
78

West Pharmaceutical Services demonstrates solid fundamental strength and positive long-term market positioning, with recent price action showing significant upward momentum. Investors should monitor short-term technical indicators for potential entry points.

Very Strong

Thematic

80

West Pharmaceutical Services is well-positioned within the healthcare sector, benefiting from trends in biologics, advanced drug delivery, and a growing demand for high-quality pharmaceutical packaging solutions.

Strong

Fundamental

81

West Pharmaceutical Services exhibits strong profitability, healthy cash flow generation, and a robust balance sheet, with consistent earnings performance and manageable debt levels.

Bullish

Technical

74

The stock has experienced a significant upward price movement recently, with strong momentum indicated by moving averages and oscillators. However, some indicators suggest it may be approaching overbought territory.

FactorScore
Biologics Growth85
Drug Delivery Innovation88
Healthcare Spending Trends75
Supply Chain Resilience70
Regulatory Landscape (Pharma Packaging)72
FactorScore
Valuation55
Profitability80
Growth65
Balance Sheet Health95
Cash Flow85
Dividend40
FactorScore
Trend Analysis85
Momentum70
Volume Confirmation75
Short-Term Indicators75
Support & Resistance65

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (7)

Earnings Performance chevron_right

Consistent EPS Surprises

The company has exceeded EPS estimates in 9 out of the last 12 reported quarters, with an average surprise of +11.12%. This demonstrates consistent operational execution and potentially underestimation by analysts.

Market Performance chevron_right

Strong Short-Term Momentum

The stock has shown significant positive performance over various short-term periods: +32.85% in 5 days, +27.44% in 1 month, and +22.78% in the current day's trading. This indicates strong current investor interest and buying pressure.

Show More 🔒
thumb_down

Bearish Points (7)

Valuation Risk chevron_right

High P/E Ratio

The Price-to-Earnings (P/E) ratio on a trailing twelve-month (TTM) basis is 41.84. This is a high multiple, suggesting that the stock may be trading at a premium relative to its current earnings, potentially limiting upside or increasing downside risk.

Growth Deceleration chevron_right

Slowing Revenue Growth

Annual revenue growth has shown a downward trend, from 23.4% in 2021 to 17.0% in 2024 (estimated based on Q4 data). This deceleration could indicate market maturity or increasing competitive pressures.

Show More 🔒

Calendar

July 2025

24

Next Earnings Date

EPS Est.
Revenue Est.

H: $1.70

A: $1.67

L: $1.65

H: 789.00M

A: 786.60M

L: 785.00M

July 2025

30

Ex-Dividend Date

August 2025

6

Next Dividend Date

Profile

Employees (FY)10.6K
ISINUS9553061055
FIGI-

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Seasonals

2025
2024
2023
2022
2021

Price Target

291.01 USD

The 39 analysts offering 1 year price forecasts for WST have a max estimate of 350.00 and a min estimate of 245.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
71.8M (99.91%)
Closely held shares
63.7K (0.09%)
71.8M
Free Float shares
71.8M (99.91%)
Closely held shares
63.7K (0.09%)

Capital Structure

Market cap
20.05B
Debt
302.3M
Minority interest
0.00
Cash & equivalents
484.6M
Enterprise value
19.87B

Valuation - Summary

Market Cap
20.1B
Net income
356M(1.77%)
Revenue
2.19B(10.93%)
20.1B
Market Cap
20.1B
Net income
356M(1.77%)
Revenue
2.19B(10.93%)
Price to earning ratio (P/E)56.40x
Price to sales ratio (P/S)9.10x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
2.89B
COGS
1.89B
Gross Profit
998.5M
OpEx
407.6M
Operating Income
590.9M
Other & Taxes
98.2M
Net Income
492.7M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒